title: FcR interactions do not play a major role in inhibition of experimental autoimmune encephalomyelitis by anti-CD154 monoclonal antibodies.
abstract: It has been demonstrated that anti-CD154 mAb treatment effectively inhibits the development of experimental autoimmune encephalomyelitis (EAE). However, although it appears to prevent the induction of Th1 cells and reactivation of encephalitogenic T cells within the CNS, little information is available regarding the involvement of alternative mechanisms, nor has the contribution of Fc effector mechanisms in this context been addressed. By contrast, efficacy of anti-CD154 mAbs in models of allotransplantation has been reported to involve long-term unresponsiveness, potentially via activation of T regulatory cells, and recently was reported to depend on Fc-dependent functions, such as activated T cell depletion through FcgammaR or complement. In this study we demonstrate that anti-CD154 mAb treatment inhibits EAE development in SJL mice without apparent long-term unresponsiveness or active suppression of disease. To address whether the mechanism of inhibition of EAE by anti-CD154 mAb depends on its Fc effector interactions, we compared an anti-CD154 mAb with its aglycosyl counterpart with severely impaired FcgammaR binding and reduced complement binding activity with regard to their ability to inhibit clinical signs of EAE and report that both forms of the Ab are similarly protective. This observation was largely confirmed by the extent of leukocyte infiltration of the CNS; however, mice treated with the aglycosyl form may display slightly more proteolipid protein 139-151-specific immune reactivity. It is concluded that FcR interactions do not play a major role in the protective effect of anti-CD154 mAb in the context of EAE, though they may contribute to the full abrogation of peripheral peptide-specific lymphocyte responses.
authors.affiliation: Division of Immunological and Infectious Diseases, The Netherlands Organization for Applied Scientific Research (TNO), Prevention and Health, Leiden, The Netherlands.
authors.forename: Lex
authors.initials: L
authors.lastname: Nagelkerken
authors.forename: Inge
authors.initials: I
authors.lastname: Haspels
authors.forename: Wouter
authors.initials: W
authors.lastname: van Rijs
authors.forename: Bep
authors.initials: B
authors.lastname: Blauw
authors.forename: Janine L
authors.initials: JL
authors.lastname: Ferrant
authors.forename: Donna M
authors.initials: DM
authors.lastname: Hess
authors.forename: Ellen A
authors.initials: EA
authors.lastname: Garber
authors.forename: Fred R
authors.initials: FR
authors.lastname: Taylor
authors.forename: Linda C
authors.initials: LC
authors.lastname: Burkly
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D023201:CD40 Ligand / Q000276:immunology*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology*; D005260:Female; D006031:Glycosylation; D051379:Mice; D018991:Myelin Proteolipid Protein / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology; D011961:Receptors, Fc / Q000276:immunology / Q000378:metabolism*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D018991:Myelin Proteolipid Protein; D010446:Peptide Fragments; D011961:Receptors, Fc; C435023:myelin proteolipid protein (139-151); D023201:CD40 Ligand